SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 15% Stake in Candel Therapeutics Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, revealing a significant 15.0% beneficial ownership stake in Candel Therapeutics Inc. as of January 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 6,318,721 shares of Candel Therapeutics Inc. common stock.
• This ownership represents 15.0% of the total outstanding common stock of Candel Therapeutics Inc.
• FMR LLC holds sole voting power over 6,318,295 shares and sole dispositive power over 6,318,721 shares.
• Abigail P. Johnson holds sole dispositive power over 6,318,721 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Select Biotechnology Portfolio is known to have the right to receive dividends or proceeds from 5,544,979 shares, representing 13.2% of the total outstanding common stock as of January 31, 2025.
• FMR LLC is identified as a parent holding company or control person, with subsidiaries like Fidelity Management & Research Company LLC (Investment Adviser), Fidelity Management Trust Company (Bank), and Strategic Advisers LLC (Investment Adviser) involved in the beneficial ownership.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. While it doesn't contain explicit sentiment, the disclosure of a significant 15% stake by a major institutional investor like FMR LLC can be implicitly viewed as a positive signal of confidence by the market, hence a slightly positive score.

Positives

• The disclosure of a substantial 15.0% beneficial ownership by a major institutional investor like FMR LLC and its affiliates may signal strong institutional confidence in Candel Therapeutics Inc.

Negatives

• The document, a Schedule 13G filing, does not contain information regarding negative aspects of Candel Therapeutics Inc.'s operations or financial performance.

Risks

• The document, a Schedule 13G filing, does not contain information regarding specific risks related to Candel Therapeutics Inc.'s business or operations.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Candel Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not provide information for broader industry trend analysis or competitor comparison within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant 15.0% stake by a major institutional investor like FMR LLC may influence investor perception and confidence in Candel Therapeutics Inc., potentially impacting its stock valuation.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Institutional Investor, Candel Therapeutics Inc., FMR LLC, Abigail P. Johnson, Common Stock, SEC Filing, Investment Management